Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Women's Health
Published in: BMC Women's Health 1/2009

Open Access 01-12-2009 | Research article

The effect of past use of oral contraceptive on bone mineral density, bone biochemical markers and muscle strength in healthy pre and post menopausal women

Authors: Fadoua Allali, Laila El Mansouri, Fatima zohra Abourazzak, Linda Ichchou, Hamza Khazzani, Loubna Bennani, Redouane Abouqal, Najia Hajjaj-Hassouni

Published in: BMC Women's Health | Issue 1/2009

Login to get access

Abstract

Background

during adulthood, most studies have reported that oral contraceptive (OC) pills had neutral, or possibly beneficial effect on bone health. We proposed this study of pre and post menopausal women assessing BMD, bone biochemical markers and physical performance among OC past users and comparable women who have never use Ocs.

Methods

A cross-sectional study comparing the bone density, bone biochemical markers (osteocalcin, CTX) and three measures to assess physical performance: timed get-up-and-go test "TGUG", five-times-sit-to-stand test "5 TSTS" and 8-feet speed walk "8 FSW" of users and never users OC. We were recruited 210 women who used OC for at least 2 years with that of 200 nonusers was carried out in pre and postmenopausal women (24-86 years).

Results

when analysing the whole population, BMD and biochemical markers values were similar for Ocs past users and control subjects. However when analysing the subgroup of premenopausal women, there was a statistically significant difference between users and never-users in osteocalcin (15,5 ± 7 ng/ml vs 21,6 ± 9 ng/ml; p = 0,003) and CTX (0,30 ± 0,1 ng/ml vs 0,41 ± 0,2 ng/ml; p = 0,025). This difference persisted after adjustment for age, BMI, age at menarche and number of pregnancies. In contrast, in post menopausal women, there was no difference in bone biochemical markers between OC users and the control. On the other hand OC past users had a significant greater performance than did the never users group. And when analysing the physical performance tests by quartile OC duration we found a significant negative association between the three tests and the use of OC more than 10 years.

Conclusion

the funding show no evidence of a significant difference in BMD between Ocs users and never user control groups, a decrease in bone turn over in OC pre menopausal users and a greater physical performances in patients who used OC up than 10 years.
Appendix
Available only for authorised users
Literature
1.
Kleerekoper M, Brienza RS, Schultz LR, Johnson CC: Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteoporosis Cooperative Research Group. Arch Intern Med. 1991, 151: 1971-6. 10.1001/archinte.151.10.1971.CrossRefPubMed
2.
Gambacciani M, Monteleone P, Ciaponi M, Sacco A, Genazzani AR: Effects of oral contraceptives on bone mineral density. Treat Endocrinol. 2004, 3: 191-6. 10.2165/00024677-200403030-00006.CrossRefPubMed
3.
Sultana S, Choudhury S, Choudhury SA: Effect of combined oral contraceptives on bone mineral density in pre and postmenopausal women. Mymensingh Med J. 2002, 11: 12-4.PubMed
4.
Pasco JA, Kotowicz MA, Henry MJ, Panahi S, Seeman E, Nicholson GC: Oral contraceptives and bone mineral density: A population-based study. Am J Obstet Gynecol. 2000, 182: 265-9. 10.1016/S0002-9378(00)70209-2.CrossRefPubMed
5.
Reed SD, Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM: Longitudinal changes in bone density in relation to oral contraceptive use. Contraception. 2003, 68: 177-82. 10.1016/S0010-7824(03)00147-1.CrossRefPubMed
6.
Wanichsetakul P, Kamudhamas A, Watanaruangkovit P, Siripakarn Y, Visutakul P: Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception. 2002, 65: 407-10. 10.1016/S0010-7824(02)00308-6.CrossRefPubMed
7.
Kuohung W, Borgatta L, Stubblefield P: Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception. 2000, 61: 77-82. 10.1016/S0010-7824(00)00086-X.CrossRefPubMed
8.
Prior JC, Kirkland SA, Joseph L, Kreiger N, Murray TM, Hanley DA, Adachi JD, Vigna YM, Berger C, Blondeau L, Jackson SA, Tenenhouse A: Oral contraceptive use and bone mineral density in premenopausal women: cross-sectional, population-based data from the Canadian Multicentre Osteoporosis Study. CMAJ. 2001, 165: 1023-9.PubMedPubMedCentral
9.
Laitinen K, Välimäki M, Keto P: Bone mineral density measured by dual-energy X-ray absorptiometry in healthy Finnish women. Calcif Tissue Int. 1991, 48: 224-31. 10.1007/BF02556372.CrossRefPubMed
10.
Sarwar R, Niclos BB, Rutherford OM: Changes in muscle strength, relaxation rate and fatiguability during the human menstrual cycle. J Physiol. 1996, 15: 267-72.CrossRef
11.
Elliott KJ, Cable NT, Reilly T: Does oral contraceptive use affect maximum force production in women?. Br J Sports Med. 2005, 39: 15-9. 10.1136/bjsm.2003.009886.CrossRefPubMedPubMedCentral
12.
Petitti DB, Piaggio G, Mehta S, Cravioto MC, Meirik O: Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol. 2000, 95: 736-44. 10.1016/S0029-7844(00)00782-1.PubMed
13.
Michaëlsson , Baron John, Farahmand Bahman, Persson Ingemar, Ljunghall Sverker: Oral-contraceptive use and risk of hip fracture: a case-control study. The Lancet. 1999, 353: 1481-1484. 10.1016/S0140-6736(98)09044-8.CrossRef
14.
Horsman A, Jones M, Francis R, Nordin C: The effect of estrogen dose on postmenopausal bone loss. N Engl J Med. 1983, 309: 1405-7.CrossRefPubMed
15.
Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A: Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol. 2004, 103: 899-906.CrossRefPubMed
16.
Kleerekoper M, Brienza RS, Schultz LR, Johnson CC: Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteoporosis Cooperative Research Group. Arch Intern Med. 1991, 151: 1971-6. 10.1001/archinte.151.10.1971.CrossRefPubMed
17.
Enzelsberger H, Metka M, Heytmanek G, Huber J: The effect of oral contraceptives on bone density in climacteric females. Zentralbl Gynakol. 1989, 111: 967-73.PubMed
18.
Garnero P, Sornay-Rendu E, Delmas PD: Decreased bone turnover in oral contraceptive users. Bone. 1995, 16: 499-503. 10.1016/8756-3282(95)00075-O.CrossRefPubMed
19.
Karlsson R, Eden S, von Schoultz B: Oral contraception affects osteocalcin serum profiles in young women. Osteoporos Int. 1992, 2: 118-21. 10.1007/BF01623817.CrossRefPubMed
20.
Karlsson KM, Karlsson C, Ahlborg HG, Valdimarsson O, Ljunghall S, Obrant KJ: Bone turnover responses to changed physical activity. Calcif Tissue Int. 2003, 72: 675-80. 10.1007/s00223-002-2052-z.CrossRefPubMed
21.
Sipilä S, Taaffe DR, Cheng S, Puolakka J, Toivanen J, Suominen H: Effects of hormone replacement therapy and high-impact physical exercise on skeletal muscle in post-menopausal women: a randomized placebo-controlled study. Clin Sci (Lond). 2001, 101: 147-57. 10.1042/CS20000271.CrossRef
22.
Ruzić L, Matković BR, Leko G: Antiandrogens in hormonal contraception limit muscle strength gain in strength training: comparison study. Croat Med J. 2003, 44: 65-8.PubMed
23.
Taaffe DR, Sipilä S, Cheng S, Puolakka J, Toivanen J, Suominen H: The effect of hormone replacement therapy and/or exercise on skeletal muscle attenuation in postmenopausal women: a yearlong intervention. Clin Physiol Funct Imaging. 2005, 25: 297-304. 10.1111/j.1475-097X.2005.00628.x.CrossRefPubMed
24.
Peters C, Burrows M: Androgenicity of the progestin in oral contraceptives does not affect maximal leg strength. Contraception. 2006, 74: 487-91. 10.1016/j.contraception.2006.08.005.CrossRefPubMed
25.
Phillips SK, Woledge RC, Bruce SA, Young A, Levy D, Yeo A, Martin FC: A study of force and cross-sectional area of adductor pollicis muscle in female hip fracture patients. J Am Geriatr Soc. 1998, 46: 999-1002.CrossRefPubMed
Metadata
Title
The effect of past use of oral contraceptive on bone mineral density, bone biochemical markers and muscle strength in healthy pre and post menopausal women
Authors
Fadoua Allali
Laila El Mansouri
Fatima zohra Abourazzak
Linda Ichchou
Hamza Khazzani
Loubna Bennani
Redouane Abouqal
Najia Hajjaj-Hassouni
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Women's Health / Issue 1/2009
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/1472-6874-9-31

Other articles of this Issue 1/2009

BMC Women's Health 1/2009 Go to the issue

Research article

Age at menarche and the menstrual pattern of secondary school adolescents in northwest Ethiopia

Research article

Factors affecting awareness of emergency contraception among college students in Kathmandu, Nepal

Research article

Reproductive and family planning history, knowledge, and needs: A community survey of low-income women in Beijing, China

Research article

Clients' reasons for prenatal ultrasonography in Ibadan, South West of Nigeria

Research article

Group treatments for sensitive health care problems: a randomised controlled trial of group versus individual physiotherapy sessions for female urinary incontinence

Research article

Delivery of chlamydia screening to young women requesting emergency hormonal contraception at pharmacies in Manchester, UK: a prospective study